A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique

Ventral Hernia Clinical Trial

Official title:
A Phase 2b Double-Blind, Placebo-Controlled, Adaptive, Dose-Escalation Study to Evaluate the Safety and Efficacy of OnabotulinumtoxinA for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique, in Subjects Undergoing Open Abdominal Ventral Hernia Repair

Status Not yet recruiting

Clinical Trial Summary

Ventral hernias form when there is a loss of integrity of the abdominal wall muscles. Abdominal hernias can expand and can cause severe pain as the abdominal wall weakens. The purpose of this study is to evaluate the safety and efficacy of a range of onabotulinumtoxinA (BOTOX) doses to achieve primary fascial closure (PFC) without use of component separation technique (CST) in ventral hernia surgical repair. BOTOX is an investigational drug being developed for the treatment of ventral hernias. In this dose escalation study, participants will be placed in 1 of 3 cohorts. Cohort 1 will be randomized to receive placebo or 1 of 2 BOTOX doses, after which time Cohort 2 will be randomized to receive placebo or 1 of 3 BOTOX doses. Participants in Cohort 3 will be randomized to receive placebo or 1 of 3 BOTOX doses. Adult participants undergoing open abdominal ventral hernia repair will be enrolled. Around 200 participants will be enrolled in the study at approximately 20 sites in the United States. Participants will receive a single intramuscular injection of BOTOX Dose A, BOTOX Dose B, BOTOX Dose C, or placebo. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will be followed for approximately 3 months after surgery and will receive a follow-up phone call 30 days (+/-) their last study visit. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05606757
Study type	Interventional
Source	AbbVie
Contact	ABBVIE CALL CENTER
Phone	844-663-3742
Email	abbvieclinicaltrials@abbvie.com
Status	Not yet recruiting
Phase	Phase 2
Start date	December 29, 2023
Completion date	May 19, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06016426` - Mass Closure vs Layer by Layer Closure	N/A
Recruiting	`NCT05572021` - A Comparison of the Outcomes in Fortiva and Strattice Mesh	N/A
Completed	`NCT02292264` - Risk Factors and Complications of Ventral Hernia Repair
Completed	`NCT02263599` - Conservative Treatment For Ventral Hernia
Completed	`NCT02263625` - Regional Differences In Indication for Ventral Hernia Repair
Completed	`NCT01961687` - A Prospective, Multi-Center Study of Phasix™ Mesh for Ventral or Incisional Hernia Repair.	N/A
Completed	`NCT01325246` - Reoperation Rate Versus Clinical Recurrence After Ventral Hernia Repair	N/A
Completed	`NCT03283982` - Laparoscopic vs. Robotic Ventral Hernia Repair With IPOM	N/A
Not yet recruiting	`NCT05526209` - Longitudinal Relaxing Incision as a Technique for Recurrence Prevention in Ventral Hernia
Completed	`NCT04438369` - Evaluation of Ultrasound-guided Erector Spinae Block for Postoperative Analgesia in Laprascopic Ventral Hernia Repair.	N/A
Recruiting	`NCT04173884` - Video-based Collaborative Learning to Improve Ventral Hernia Repair	N/A
Recruiting	`NCT02703662` - Performance of Biologic Mesh Materials in Abdominal Wall Reconstruction	Phase 2/Phase 3
Completed	`NCT03938688` - Randomized Control Trial Comparing Transfascial Suture for Mesh Fixation to No Mesh Fixation	N/A
Active, not recruiting	`NCT01719718` - The Influence of Closing the Gap on Postoperative Seroma and Recurrences in Laparoscopic Ventral Hernia Repair	N/A
Completed	`NCT03342040` - Transverse Abdominis Plane Block in Laparoscopic Ventral Hernia Repair	N/A
Completed	`NCT04150796` - Comparing eTEP and Laparoscopic Intraperitoneal Onlay Mesh (IPOM) for Ventral Hernias	N/A
Recruiting	`NCT03222102` - Ventral Hernia Prevention After Liver Transplantation	N/A
Completed	`NCT05610267` - Gentrix® Surgical Matrix for Soft Tissue Reinforcement in Ventral Hernia Repair
Terminated	`NCT01794338` - The Use of Biologic Mesh vs Bioabsorbable Mesh During Ventral Hernia Repair in At-risk Patients	N/A
Completed	`NCT01886963` - A Clinical Trial Using Spy Elite System in Planning Tissue Advancement Flaps After Ventral Hernia Repair	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.